Nautilus Biotech will discover novel recombinant Factor IX proteins and MediVas will discover biopharmaceuticals that extend the duration of action of current treatments.
Wyeth Pharmaceuticals signed two separate agreements to improve its hemophilia program with MediVas and Nautilus Biotech. Wyeth reports that it currently markets the only recombinant Factor IX product, BeneFIX Coagulation Factor IX (recombinant).
The research collaboration with MediVas was initiated to discover, develop, manufacture, and commercialize biopharmaceuticals that extend the duration of action of recombinant factor treatments for hemophilia. MediVas will employ a unique polymer-based drug delivery system to develop advanced delivery methods. The company will work to create a longer half-life for these proteins.
MediVas will receive milestone and royalty payments based on net sales of products. Wyeth will research, develop, manufacture, and market any products derived from the agreement.
The research and license partnership with Nautilus Biotech aims to discover and develop novel recombinant Factor IX proteins for hemophilia B. Nautilus Biotech will apply its technology to improve the duration of action of recombinant hemophilia B therapy and thus reduce the number and frequency of treatments needed.
The Nautilus Biotech technology makes minimal and specific changes to the amino acid sequence to slow the breakdown of the protein in the body.
